多模态监测在神经重症患者中的应用研究
该研究纳入福建省立医院重症医学科2019年3月至2020年1月收治的104例神经重症患者,随机分为常规监测组和多模态监测组各52例。多模态监测组采用有创颅内压监测、超声评估脑结构、视神经鞘直径测量、经颅彩色多普勒、颈内静脉血氧饱和度监测、近红外光谱、无创脑血氧饱和度监测和定量脑电图,并根据监测结果进行靶向治疗。结果显示多模态监测组ICU住院时间显著缩短(6.27±3.81天 vs 9.61±5.09天,P<0.01),神经系统并发症发生率显著降低(9.62% vs 25.00%,P<0.05),不良预后发生率显著降低(28.85% vs 48.08%,P<0.05)。有创颅内压预测不良预后的AUC为0.906,最佳截断值为≥18 mmHg。
要点
- 多模态监测组ICU住院时间6.27±3.81天,显著短于常规监测组的9.61±5.09天(P<0.01)。
- 多模态监测组神经系统并发症发生率9.62%,显著低于常规监测组的25.00%(P<0.05)。
- 多模态监测组不良预后(6个月GOS 1~3分)发生率28.85%,显著低于常规监测组的48.08%(P<0.05)。
- 有创颅内压预测不良预后的AUC为0.906,最佳截断值≥18 mmHg,灵敏度86.49%,特异度86.67%。
- 大脑中动脉搏动指数预测不良预后的AUC为0.759,最佳截断值≥1.12,灵敏度81.08%,特异度60.00%;有创颅内压的AUC大于大脑中动脉搏动指数(Z=2.279,P=0.023)。
适用人群与场景
- 福建省立医院重症医学科2019年3月至2020年1月收治的神经重症患者104例,随机分为常规监测治疗组和多模态监测治疗组各52例。
处置流程与药物剂量
- 常规监测治疗组:术后监测心率、血压、呼吸频率及意识和瞳孔变化,给予常规药物降低颅内压、维持适当脑灌注压、平衡液体出入量、保持气道通畅。
- 多模态监测治疗组:采用有创颅内压监测、超声评估脑结构、超声测量视神经鞘直径、经颅彩色多普勒、颈内静脉血氧饱和度监测、近红外光谱、无创脑血氧饱和度监测和定量脑电图监测,根据监测结果以控制颅内压和改善脑代谢为目标给予靶向治疗。
研究设计与关键结果
- 研究类型为随机对照研究,纳入104例神经重症患者,随机分为常规监测治疗组和多模态监测治疗组各52例。
- 多模态监测治疗组ICU住院时间6.27±3.81天,显著短于常规监测治疗组的9.61±5.09天(P<0.01)。
- 多模态监测治疗组神经系统并发症(继发性脑梗死、脑出血、高颅内压等)发生率9.62%,显著低于常规监测治疗组的25.00%(P<0.05)。
- 多模态监测治疗组预后良好37例、预后不良15例,常规监测治疗组预后良好27例、预后不良25例;多模态监测治疗组不良预后发生率28.85%,显著低于常规监测治疗组的48.08%(P<0.05)。
- 多模态监测治疗组中,预后良好患者的有创颅内压和大脑中动脉搏动指数均显著低于预后不良患者[有创颅内压(mmHg):16(12,17)vs 22(20,24),大脑中动脉搏动指数:0.90±0.33 vs 1.39±0.58,均P<0.01];大脑中动脉阻力指数在预后良好组与预后不良组间无显著差异(0.63±0.12 vs 0.66±0.15,P>0.05)。
- 有创颅内压与经颅彩色多普勒计算的颅内压值呈正相关(r=0.767,P<0.001)。
- 有创颅内压预测不良预后的AUC为0.906,最佳截断值≥18 mmHg,灵敏度86.49%,特异度86.67%;大脑中动脉搏动指数预测不良预后的AUC为0.759,最佳截断值≥1.12,灵敏度81.08%,特异度60.00%;有创颅内压的AUC大于大脑中动脉搏动指数(Z=2.279,P=0.023)。
证据类型、等级与局限
- 证据类型为随机对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,综合分析神经重症患者的多模态监测指标以指导临床治疗,可缩短住院时间、降低神经外科并发症和残疾风险。
- 作者认为,有创颅内压可预测神经重症患者的不良预后。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the significance of multimodal monitoring in the monitoring and treatment of neurocritical care patients.
METHODS: 104 neurocritical care patients admitted to the department of Critical Care Medicine of Fujian Provincial Hospital from March 2019 to January 2020 were enrolled. Patients were randomly assigned into two groups, with 52 in each group. In the routine monitoring treatment group, heart rate, blood pressure, respiratory rate and the changes in consciousness and pupils were monitored after operation. The patients were treated with routine medicine to reduce intracranial pressure (ICP), maintain proper cerebral perfusion pressure (CPP), balance fluid intake and output, and maintain the airway clear. Patients in the multimodal monitoring treatment group were treated with invasive ICP monitoring, ultrasound to assess brain structure, ultrasound to measure optic nerve sheath diameter (ONSD), transcranial color doppler (TCCD), internal jugular venous blood oxygen saturation monitoring, near-infrared spectroscopy (NIRS), non-invasive cerebral blood oxygen saturation monitoring and quantitative electroencephalogram monitoring. According to the monitoring results, the patients were given targeted treatment with the goal of controlling ICP and improving brain metabolism. The length of intensive care unit (ICU) stay, the incidences of neurological complications (secondary cerebral infarction, cerebral hemorrhage, high intracranial pressure, etc.), and the incidences of poor prognosis [6 months after the onset of Glasgow outcome score (GOS) 1 to 3] were compared between the two groups. Spearman rank correlation analysis of the correlation between invasive ICP and the ICP value which was calculated by TCCD. The receiver operating characteristic (ROC) curve of invasive ICP and pulsatility index of middle cerebral artery (PIMCA) were used to predict poor prognosis.
RESULTS: The length of ICU stay in the multimodal monitoring treatment group was significantly shorter than that of the routine monitoring treatment group (days: 6.27±3.81 vs. 9.61±5.09, P < 0.01), and the incidence of neurological complications was significantly lower than that in the routine monitoring treatment group (9.62% vs. 25.00%, P < 0.05). In the multimodal monitoring treatment group, 37 cases had a good prognosis and 15 cases had a poor prognosis, while the routine monitoring treatment group had a good prognosis in 27 cases and a poor prognosis in 25 cases. The incidence of poor prognosis in the multimodal monitoring treatment group was lower than that of the routine monitoring treatment group (28.85% vs. 48.08%, P < 0.05). In the multimodal monitoring treatment group, the invasive ICP and PIMCA of patients with good prognosis were significantly lower than those of patients with poor prognosis [invasive ICP (mmHg, 1 mmHg = 0.133 kPa): 16 (12, 17) vs. 22 (20, 24), PIMCA: 0.90±0.33 vs. 1.39±0.58, both P < 0.01]. There was no significant difference in resistance index of the middle cerebral artery (RIMCA) between the good prognosis group and the poor prognosis group (0.63±0.12 vs. 0.66±0.15, P > 0.05). There was a positive correlation between the invasive ICP and the ICP value which was calculated by TCCD (r = 0.767, P < 0.001). ROC curve analysis showed that the area under ROC curve (AUC) of invasive ICP for poor prognosis prediction was 0.906, the best cut-off value was ≥ 18 mmHg, the sensitivity was 86.49%, and the specificity was 86.67%. The AUC of PIMCA for poor prognosis prediction was 0.759, the best cut-off value was ≥ 1.12, the sensitivity was 81.08%, and the specificity was 60.00%. The AUC of invasive ICP was greater than PIMCA (Z = 2.279, P = 0.023).
CONCLUSIONS: Comprehensive analysis of multimodal monitoring indicators for neurocritical care patients to guide clinical treatment can reduce the length of hospital stay, and reduce the risk of neurosurgery complications and disability; invasive ICP can predict poor prognosis of neurocritical care patients.
参考来源
- Zhou X, Chen H, Yu R, et al. [Study of multimodal monitoring in neurocritical care patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32912410. doi:10.3760/cma.j.cn121430-20200130-00148
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。